News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
73–74
Matches
74
Sources here
2
Companies here
1
Search results Stored financial headlines

Active search

74 matching headlines

Ticker or company: IBRXMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

ACCESS Newswire Regulatory and legal Main company 🇺🇸 United States

ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ImmunityBio, Inc. (IBRX) regarding potential corporate wrongdoing by its officers and directors. The law firm is encouraging shareholders who purchased ImmunityBio securities before January 19, 2026, and still hold them, to contact the firm …

IBRX main company
Sharemaestro market context Price below Trend Line 52 weeks +227.7% IBRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Earnings Main company 🇺🇸 United States

Are Surging IBRX Retail Debates Hinting at a Deeper Re‑rating of ImmunityBio’s Platform?

ImmunityBio (IBRX) is awaiting an FDA decision on its drug Anktiva for bladder cancer, with a PDUFA date of January 6, 2027. This regulatory milestone, combined with increasing retail investor interest, is influencing sentiment around the broader immunotherapy platform. The company's investment narrative projects …

IBRX main company
Sharemaestro market context Price below Trend Line 52 weeks +227.7% IBRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context